Advertisement


Brendan J. Guercio, MD, on Colorectal Cancer and Physical Activity: Impact on Survival

2017 Gastrointestinal Cancers Symposium

Advertisement

Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).



Related Videos

Gastrointestinal Cancer

Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial

Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).

Colorectal Cancer

Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Gastroesophageal Cancer

Karyn A. Goodman, MD, on Esophageal Cancer: Results of CALGB 80803

Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).

Gastrointestinal Cancer

Salah-Eddin Al-Batran, MD, on Gastric Cancer: RADPAC Trial Results

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).

Advertisement

Advertisement




Advertisement